Compare Stocks: NAMS, KRYS, PTGX, and KYMR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRYS Krystal Biotech	$318.32 +0.5%	$340.41	$183.03 ▼ $382.54	$9.43B	0.5	326,410 shs	1,094 shs
KYMR Kymera Therapeutics	$106.38 +1.5%	$115.19	$55.26 ▼ $130.05	$8.84B	1.98	744,478 shs	154 shs
NAMS NewAmsterdam Pharma	$20.16 +1.6%	$24.19	$19.58 ▼ $42.21	$2.36B	0.1	1.14 million shs	1,556 shs
PTGX Protagonist Therapeutics	$130.59 +1.4%	$145.39	$73.08 ▼ $160.81	$8.29B	1.53	830,588 shs	886,739 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRYS Krystal Biotech	0.00%	-4.53%	-5.97%	-6.67%	+66.42%
KYMR Kymera Therapeutics	0.00%	-6.78%	-11.01%	-5.65%	+75.13%
NAMS NewAmsterdam Pharma	0.00%	-8.11%	-11.83%	-33.16%	-45.52%
PTGX Protagonist Therapeutics	0.00%	-10.42%	-9.97%	-4.11%	+66.13%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRYS Krystal Biotech	$318.32 +0.5%	$340.41	$183.03 ▼ $382.54	$9.43B	0.5	326,410 shs	1,094 shs
KYMR Kymera Therapeutics	$106.38 +1.5%	$115.19	$55.26 ▼ $130.05	$8.84B	1.98	744,478 shs	154 shs
NAMS NewAmsterdam Pharma	$20.16 +1.6%	$24.19	$19.58 ▼ $42.21	$2.36B	0.1	1.14 million shs	1,556 shs
PTGX Protagonist Therapeutics	$130.59 +1.4%	$145.39	$73.08 ▼ $160.81	$8.29B	1.53	830,588 shs	886,739 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRYS Krystal Biotech	0.00%	-4.53%	-5.97%	-6.67%	+66.42%
KYMR Kymera Therapeutics	0.00%	-6.78%	-11.01%	-5.65%	+75.13%
NAMS NewAmsterdam Pharma	0.00%	-8.11%	-11.83%	-33.16%	-45.52%
PTGX Protagonist Therapeutics	0.00%	-10.42%	-9.97%	-4.11%	+66.13%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KRYS Krystal Biotech	3.00	Buy	$377.20	18.50% Upside
KYMR Kymera Therapeutics	2.89	Moderate Buy	$134.68	26.61% Upside
NAMS NewAmsterdam Pharma	2.83	Moderate Buy	$48.90	142.62% Upside
PTGX Protagonist Therapeutics	3.11	Buy	$154.44	18.26% Upside

Current Analyst Ratings Breakdown

Latest NAMS, KRYS, PTGX, and KYMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	KYMR Kymera Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	NAMS NewAmsterdam Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/15/2026	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$361.00
10/14/2026	PTGX Protagonist Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
10/12/2026	PTGX Protagonist Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$184.00
10/12/2026	PTGX Protagonist Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/12/2026	PTGX Protagonist Therapeutics	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$150.00 ➝ $190.00
10/9/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy (B) ➝ Buy (B-)
10/8/2026	KYMR Kymera Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$140.00
10/8/2026	PTGX Protagonist Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C+) ➝ Buy (B-)

(Data available from 10/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KRYS Krystal Biotech	$389.13M	24.21	$7.33 per share	43.43	$42.06 per share	7.57
KYMR Kymera Therapeutics	$39.21M	225.58	N/A	N/A	$19.42 per share	5.48
NAMS NewAmsterdam Pharma	$7.12M	338.33	N/A	N/A	$5.97 per share	3.38
PTGX Protagonist Therapeutics	$46.02M	183.63	N/A	N/A	$9.83 per share	13.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KRYS Krystal Biotech	$204.83M	$7.98	39.91	35.37	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)
KYMR Kymera Therapeutics	-$311.35M	-$3.24	N/A	N/A	N/A	-285.33%	-21.22%	-19.21%	11/3/2026 (Estimated)
NAMS NewAmsterdam Pharma	-$203.82M	-$2.16	N/A	N/A	N/A	-3,644.21%	-34.81%	-31.50%	11/4/2026 (Estimated)
PTGX Protagonist Therapeutics	-$130.15M	$1.03	124.42	N/A	N/A	29.40%	12.03%	11.23%	11/5/2026 (Estimated)

Latest NAMS, KRYS, PTGX, and KYMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	PTGX Protagonist Therapeutics	$2.39	N/A	N/A	N/A	$229.92 million	N/A
11/4/2026	Q3 2026	NAMS NewAmsterdam Pharma	-$0.4949	N/A	N/A	N/A	$7.54 million	N/A
11/3/2026	Q3 2026	KYMR Kymera Therapeutics	-$1.27	N/A	N/A	N/A	$3.10 million	N/A
11/2/2026	Q3 2026	KRYS Krystal Biotech	$1.84	N/A	N/A	N/A	$126.77 million	N/A
8/5/2026	Q2 2026	KYMR Kymera Therapeutics	-$0.7126	-$0.62	+$0.0926	-$0.62	$32.78 million	$65.00 million
8/5/2026	Q2 2026	NAMS NewAmsterdam Pharma	-$0.4819	-$0.52	-$0.0381	-$0.52	$2.83 million	$3.70 million
8/5/2026	Q2 2026	PTGX Protagonist Therapeutics	$2.27	$2.29	+$0.02	$2.29	$212.03 million	$213.48 million
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KRYS Krystal Biotech	N/A	8.32	7.96
KYMR Kymera Therapeutics	N/A	10.34	10.34
NAMS NewAmsterdam Pharma	N/A	9.03	9.03
PTGX Protagonist Therapeutics	N/A	21.71	21.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KRYS Krystal Biotech	86.29%
KYMR Kymera Therapeutics	N/A
NAMS NewAmsterdam Pharma	89.89%
PTGX Protagonist Therapeutics	98.63%

Insider Ownership

Company	Insider Ownership
KRYS Krystal Biotech	13.10%
KYMR Kymera Therapeutics	15.98%
NAMS NewAmsterdam Pharma	12.74%
PTGX Protagonist Therapeutics	5.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KRYS Krystal Biotech	295	29.60 million	25.72 million	Optionable
KYMR Kymera Therapeutics	273	83.15 million	69.86 million	Optionable
NAMS NewAmsterdam Pharma	100	119.54 million	104.31 million	Optionable
PTGX Protagonist Therapeutics	141	64.71 million	61.35 million	Optionable

NAMS, KRYS, PTGX, and KYMR Headlines

Recent News About These Companies

Comparing Sarepta Therapeutics (NASDAQ:SRPT) and Protagonist Therapeutics (NASDAQ:PTGX)

1 hour ago | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Raised to Strong-Buy at Zacks Research

October 16 at 6:29 AM | marketbeat.com

Citi keeps Buy rating for Protagonist Therapeutics stock

October 15, 2026 | ad-hoc-news.deA

Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know

October 15, 2026 | zacks.com

Protagonist Therapeutics (NASDAQ:PTGX) Raised to "Strong-Buy" at UBS Group

October 14, 2026 | marketbeat.com

UBS sets USD 184.00 target for Protagonist Therapeutics stock

October 13, 2026 | ad-hoc-news.deA

Head to Head Contrast: Protagonist Therapeutics (NASDAQ:PTGX) & AbCellera Biologics (NASDAQ:ABCL)

October 13, 2026 | americanbankingnews.com

UBS initiates coverage of Protagonist Therapeutics with buy rating

October 12, 2026 | msn.com

Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology

October 12, 2026 | msn.com

UBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price Target

October 12, 2026 | marketscreener.comM

Protagonist Therapeutics' (PTGX) Outperform Rating Reaffirmed at Leerink Partners

October 12, 2026 | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Stock Keeps "Outperform" Rating at Leerink Partners

October 12, 2026 | marketbeat.com

Protagonist Therapeutics (NASDAQ:PTGX) & Halozyme Therapeutics (NASDAQ:HALO) Financial Survey

October 11, 2026 | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Stock Rating Cut to Buy at Wall Street Zen

October 10, 2026 | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Stock Rating Cut to "Buy" at Wall Street Zen

October 10, 2026 | marketbeat.com

Protagonist Therapeutics stock fell 1.38 percent on October 6

October 6, 2026 | ad-hoc-news.deA

Protagonist Therapeutics (NASDAQ:PTGX) Stock: Insider Asif Ali Sells 58,629 Shares

October 3, 2026 | insidertrades.com

Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CFO Sells 58,629 Shares of Company Stock

October 2, 2026 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Has Consensus Price Target of $147.13 According to Analysts

October 2, 2026 | marketbeat.com

Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up - What's Next?

September 25, 2026 | marketbeat.com

Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 7,278 Shares

September 11, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS, KRYS, PTGX, and KYMR Company Descriptions

Krystal Biotech NASDAQ:KRYS

$318.32 +1.74 (+0.55%)

As of 09:33 AM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Kymera Therapeutics NASDAQ:KYMR

$106.38 +1.60 (+1.52%)

As of 09:34 AM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

NewAmsterdam Pharma NASDAQ:NAMS

$20.11 +0.28 (+1.42%)

As of 09:33 AM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Protagonist Therapeutics NASDAQ:PTGX

$130.59 +1.84 (+1.43%)

As of 09:34 AM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NAMS, KRYS, PTGX, and KYMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NAMS, KRYS, PTGX, and KYMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NAMS, KRYS, PTGX, and KYMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS, KRYS, PTGX, and KYMR Company Descriptions

Krystal Biotech NASDAQ:KRYS

Kymera Therapeutics NASDAQ:KYMR

NewAmsterdam Pharma NASDAQ:NAMS

Protagonist Therapeutics NASDAQ:PTGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NAMS, KRYS, PTGX, and KYMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NAMS, KRYS, PTGX, and KYMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NAMS, KRYS, PTGX, and KYMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS, KRYS, PTGX, and KYMR Company Descriptions

Krystal Biotech NASDAQ:KRYS

Kymera Therapeutics NASDAQ:KYMR

NewAmsterdam Pharma NASDAQ:NAMS

Protagonist Therapeutics NASDAQ:PTGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools